OptimizeRx Corporation

NASDAQ:OPRX

Medical - Healthcare Information Services

Healthcare
$7.31 -0.98%

-$0.05 today

Market cap
$138.21M
Beta
1.10
P/E (TTM)
13.8
EPS (TTM)
$0.36
52W Low $4.57High $22.25

Volume 0.18M

Average 0.47M

OPRX Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

OptimizeRx CorporationNASDAQ: OPRX

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q1 FY2026 capital expenditures of $21K (cash outflow) fell 22.2% year over year, ahead of the -84.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 90.9% from the prior quarter. Over 3 fiscal years it compounded at -38.1% a year.

Context

  • Capital expenditures amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -22.2% holds above the trailing-twelve-month pace of -84.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21K+90.9% QoQ
Last fiscal yearDec 2025
-$58K-48.2% YoY
LTMMar 2026
-$52K-84.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.2%——
1 year-48.2%——
3-year CAGR-38.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(58K) USD
Year-over-year change
+48.2%

Capital Expenditures vs competitors

How OPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -84.0% is the 8th highest of 9, against a peer median of -45.1%.
  • Capital expenditures amounts to 0.0% of revenue for OPRX, versus a peer median of 2.3%.
OPRX Competitors
Capital Expenditures for OPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRCNational Research CorporationLTM Mar 2026$9.55M USD-33.2%+2.9%6.9%
TBRGTruBridge, Inc.LTM Mar 2026$4.68M USD-74.6%-59.1%1.4%
RXSTRxSight, Inc.LTM Mar 2026$4.01M USD-0.8%+17.0%3.1%
SPOKSpok Holdings, Inc.LTM Mar 2026$3.61M USD+17.3%-0.2%2.6%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$3.31M USD-57.1%-61.9%4.1%
DHDefinitive Healthcare Corp.LTM Mar 2026$2.22M USD-88.8%+26.2%0.9%
SLPSimulations Plus, Inc.LTM Feb 2026$1.51M USD-17.8%-43.6%1.9%
NAKANakamoto Inc.LTM Mar 2026$61.38K USD-64.9%-9.6%1.6%
OPRXOptimizeRx CorporationLTM Mar 2026$52K USD-84.0%-38.1%0.0%
DRUGBright Minds Biosciences Inc.LTM Mar 2026CA$4.18 CAD———
Peer median (excluding OPRX) —-45.1%-4.9%2.3%

Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income378.08K(11.44M)(17.57M)(20.11M)5.13M
Depreciation & Amortization1.97M2.02M2.4M4.33M4.33M
Deferred Income Tax0001.45M1.21M
Stock-Based Compensation5.49M15.75M13.72M11.47M6.96M
Change in Working Capital(7.19M)3.96M(15.55M)921K816K
Accounts Receivables(6.99M)2.28M(8.71M)(2.17M)460K
Inventory00000
Accounts Payables(603.09K)555.4K195K(72K)(520K)
Other Working Capital408.65K1.12M(7.03M)3.16M876K
Other Non-Cash Items80K363.51K9.76M6.83M264K
Operating Cash Flow726.04K10.65M(7.24M)4.89M18.72M
Capital Expenditures(486K)(244.57K)(871K)(112K)(58K)
Acquisitions (Net)0(2M)(80.41M)00
Purchases of Investments0(55.93M)(162.78M)00
Sales of Investments00218.71M00
Other Investing Activities(385.68K)(163.56K)(774K)(338K)126K
Investing Cash Flow(486K)(58.18M)(25.34M)(450K)68K
Debt Repayment0036.02M(4M)(8M)
Common Stock Issued70.67M000352K
Common Stock Repurchased0(20.02M)(7.52M)(911K)0
Dividends Paid00000
Other Financing Activities3.25M1.07M(278K)0(1.15M)
Financing Cash Flow73.92M(18.95M)28.22M(4.91M)(8.8M)
Effect of Forex Changes00000
Net Change in Cash74.16M(66.47M)(4.36M)(472K)9.99M
Free Cash Flow240.04K10.41M(8.11M)4.78M18.66M

OptimizeRx Corporation

NASDAQ:OPRX

Intrinsic Alpha fair value

Locked

Current Price

$7.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.